Established in 2016, Institute for Precision Medicine and Innovative Drug (PMID) in Hong Kong Baptist University is an integrated research academic institute of scientific research, R&D of product and talent training. Prof. Aiping Lu is the Director of the institute.

The mission of the Institute for Precision Medicine and Innovative Drug in Hong Kong Baptist University is to analyze and authenticate the biomarker of large-sample crowd and special disease type, and to conduct verification and application of such biomarker. That is how it can find out the exact cause of disease and determine a therapeutic target precisely. Furthermore, it can classify different stage of a certain disease accurately so as to realize personalized precision therapy on special disease and patients. By doing so, benefit and effectiveness of diagnosis treatment and prevention would be improved. Meanwhile, it is committed to create medicines with self-owned intellectual property, which has good therapeutic action on serious disease, so as to rely less on innovative foreign medicines.

The objective of the Institute for Precision Medicine and Innovative Drug is to provide communication and discussion platform opportunity of interdisciplinary and cross-science development for practitioners in life science and medicine, enabling such people to have in-depth knowledge of research process and achievements in each and every field of life science and medicine. Through exchange and discussion, by bringing together the wisdom of each and every science researcher, we have commitment to contributing to the growth of the industry and human health. In order to reach the goal, by blending various disciplines such as gene sequencing, biological information and big data, the Institute for Precision Medicine and Innovative Drug actively promote the rapid development of all aspects of production, science and research in precision medicine and creative drugs.